Crinetics Pharmaceuticals, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company generated total revenue of $25.1 million for the quarter, a substantial increase from $1.0 million in the same period last year, primarily driven by the launch of its first commercial product, PALSONIFY® (paltusotine). For the first half of 2026, total revenue reached $35.9 million, compared to $1.4 million in the first half of 2025. The product revenue from PALSONIFY accounted for $24.0 million in the second quarter and $34.3 million for the first six months, marking a notable transition from a clinical-stage to a commercial-stage company.
Operating expenses for the second quarter of 2026 totaled $157.6 million, up from $130.1 million in the same quarter of the previous year. This increase was attributed to higher research and development costs, which rose to $99.9 million from $80.3 million year-over-year, as the company advanced its clinical programs. Selling, general, and administrative expenses also increased to $57.6 million from $49.8 million, reflecting investments in commercial infrastructure to support PALSONIFY's launch. Despite the revenue growth, Crinetics reported a net loss of $120.9 million for the quarter, slightly higher than the $115.6 million loss in the prior year.
In terms of operational metrics, Crinetics reported that 385 unique healthcare providers prescribed PALSONIFY within the first three quarters of its launch, with over 70% of patients treated being on reimbursed therapy. The company also received 245 enrollment forms during the second quarter, indicating strong uptake among patients and healthcare providers. The company is actively pursuing geographic expansion, with PALSONIFY recently approved in the European Union and an application submitted to Brazil’s ANVISA for approval.
Crinetics' balance sheet showed total assets of $1.32 billion as of June 30, 2026, up from $1.13 billion at the end of 2025. The increase was primarily due to a rise in cash and investment securities, which totaled $1.2 billion. The company’s accumulated deficit grew to $1.67 billion, reflecting ongoing investments in research and development and commercialization efforts. Looking ahead, Crinetics anticipates continued net losses as it focuses on expanding its product offerings and advancing its pipeline, which includes atumelnant and other investigational candidates. The company also announced a merger agreement with Vertex Pharmaceuticals, expected to close in the third quarter of 2026, which may impact its future financial and operational strategies.
About Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals is a clinical-stage biotech focused on developing oral, nonpeptide therapeutics targeting peptide GPCRs for endocrine diseases and tumors. Its pipeline includes treatments for acromegaly, carcinoid syndrome, and other hormonal disorders, emphasizing improved efficacy, safety, and patient convenience. The company leverages expertise in endocrine pathways, with proprietary molecules designed to address unmet medical needs in endocrinology and oncology markets.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov